OncoHost
OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy. Its PROphet® platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers.
- Company typePrivate
- Founded2017
- HeadquartersBinyamina, Israel
- Headcount11–50
- GTM typeB2B
- OfferingServices
What OncoHost does
OncoHost is a clinical-stage precision oncology company founded in 2017 in Binyamina, Israel, that develops AI-powered plasma proteomics diagnostics to predict cancer patient response to immunotherapy. The company's flagship PROphet® platform uses machine learning algorithms trained on data from over 1,700 patients across 40+ clinical trial sites to analyze more than 7,000 circulating proteins per blood sample, generating a personalized PROphet Score (0-10) that predicts clinical benefit from PD-1/PD-L1 inhibitor therapy. The underlying proteomic measurement relies on a licensed SomaScan® assay (from SomaLogic) utilizing Slow-Off-Rate Modified Aptamers (SOMAmers), with proprietary serum-plasma proteomic bridging methodology enabling integration of heterogeneous datasets across studies.
The commercial product portfolio currently centers on PROphetNSCLC®, launched in the U.S. in February 2023 for first-line treatment decisions in metastatic non-small cell lung cancer, with PROphetRCC™ available for renal cell carcinoma and NeutroFlow (a rapid point-of-care test) in development under a €2.5 million EIC Transition grant. Revenue is generated via transaction-fee diagnostic testing services, with OncoHost billing patient insurance directly through its CLIA-certified, CAP-accredited laboratory in Cary, North Carolina, and offering a multi-channel ordering infrastructure (online physician portal, fax-based TRF, mobile phlebotomy) supported by Regional Sales Directors.
Go-to-market is enterprise field sales targeting oncologists and cancer treatment centers — the platform has been adopted across approximately 200 U.S. cancer centers, with reported clinical impact that 93% of oncologists adjust treatment recommendations based on PROphet results. The company serves two principal customer segments: oncologists/cancer centers (primary, for clinical decision-making) and pharmaceutical companies (secondary, for clinical trial patient stratification and companion diagnostic applications, evidenced by partnerships with Henlius, Roswell Park, and others). Operating geographies span North America (U.S. commercial), the Middle East (Israeli R&D headquarters), and Europe (UK NHS clinical trial sites, EU collaborations).
OncoHost firmographics
Firmographics- Name
- OncoHost
- Legal name
- OncoHost, Inc.
- Website
- https://oncohost.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy. Its PROphet® platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers.
- Ownership category
- akta.pro rank
OncoHost industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where OncoHost is headquartered
LocationHeadquarters
- HQ city
- Binyamina
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
OncoHost business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Laboratory Diagnostic Testing Services: OncoHost generates revenue through its CLIA-certified laboratory providing the PROphetNSCLC test. The company bills patient insurance directly, with financial assistance available for qualifying patients. Patients may receive Explanation of Benefits from insurance but are only responsible for co-insurance based on plan-allowed amounts without balance billing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Insurance-billed diagnostic test |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
OncoHost product offering
Product offeringCore offering
OncoHost develops and commercializes the PROphet® platform, an AI-powered plasma proteomics diagnostic that uses the SomaScan assay (measuring ~7,000 circulating proteins per sample) to generate a personalized PROphet® Score predicting clinical benefit from PD-1/PD-L1 inhibitor immunotherapy. The commercially launched PROphetNSCLC® test supports first-line treatment decisions for metastatic non-small cell lung cancer, processed through the company's CLIA-certified laboratory in Cary, North Carolina.
Product overview
OncoHost offers a precision oncology platform centered on the PROphet® AI-powered plasma proteomics system. The core PROphet® Platform analyzes over 7,000 circulating proteins per patient using machine learning to generate predictive scores for immunotherapy response. Two diagnostic tests have been commercialized: PROphetNSCLC® for non-small cell lung cancer and PROphetRCC™ for renal cell carcinoma. A third test, NeutroFlow, is in development as a rapid point-of-care solution. The platform integrates SomaScan® assay technology (licensed from SomaLogic) for high-throughput proteomic profiling of blood samples prior to treatment initiation.
Differentiator
Problem solved
Functional benefit
Brands
- PROphet®: AI-powered plasma proteomics platform that predicts patient response to immunotherapy and generates personalized PROphet® scores for treatment decision support.
Products and services
- PROphetNSCLC® Test Blood-based diagnostic test intended for managing non-resectable stage III and IV non-small cell lung cancer (NSCLC) patients treated with first-line anti-PD-1/PD-L1-based therapy as a single agent or in combination with chemotherapy. Provides a personalized PROphet® Score between 0-10 with POSITIVE (5-10) or NEGATIVE (0-5) classification.
- PROphetRCC™ Test Treatment decision tool for newly diagnosed stage IV Renal Cell Carcinoma (RCC) patients being considered for treatment with immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) in the first-line setting.
- PROphet® Platform AI-powered plasma proteomics platform that uses machine learning to analyze over 7,000 circulating proteins per patient and generate a personalized PROphet® Score predicting clinical benefit from immunotherapy (PD-1/PD-L1 inhibitors). Underlies the company's commercial diagnostic tests.
Quantifiable outcome
- 93% of oncologists adjust treatment recommendations with PROphetNSCLC test
- +2 more outcomes
Companies that use OncoHost
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
OncoHost technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
OncoHost partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered key, supporting and core.
- National Cancer Institute (NCI)keyMulti-institutional collaboration on landmark JPBA study demonstrating serum-plasma proteomic bridging methodology. NCI researchers collaborated with OncoHost scientific team on high-throughput proteomic profiling research.
- Yale School of MedicinekeyMulti-institutional collaboration on JPBA study developing computational framework for integrating serum and plasma proteomic datasets for biomarker studies.
- Heidelberg University HospitalkeyCollaborated with OncoHost on serum-plasma proteomic bridging study published in Journal of Pharmaceutical and Biomedical Analysis. Previously partnered on lung cancer biomarkers research (December 2021).
- ions.biosupportingBiomarker development company collaborating with OncoHost and other institutions on serum-plasma proteomic bridging research published in JPBA.
- Gustave Roussy Cancer InstitutekeyPartnership to advance predictive markers for immune-related adverse events (irAEs). Research collaboration focusing on identifying biomarkers that can predict which patients will experience adverse events from immunotherapy.
- Baylor Scott & White Research InstitutesupportingCollaborative research study to analyze resistance mechanisms in lung cancer patients, combining institutional expertise with OncoHost's proteomic analysis capabilities.
- TGen (Translational Genomics Research Institute)supportingPartnered with Baylor Scott & White Research Institute and OncoHost to investigate resistance mechanisms in lung cancer using advanced genomic and proteomic approaches.
- HenliuskeyOncoHost's PROphet platform supporting Henlius US-based Phase III trial for patients with extensive-stage small cell lung cancer (SCLC), providing biomarker analysis for patient stratification.
- BGN TechnologiessupportingCollaboration to predict cancer patient response to anti-PD-1 treatment using IcAR Biosensing Technology, combining BGN's biosensing expertise with OncoHost's proteomic platform.
- SomaLogic Inc.coreSomaLogic granted OncoHost a license to use the SomaScan assay platform for the development of precision cancer diagnostics. The SomaScan platform uses Slow-Off-Rate Modified Aptamers (SOMAmers) to measure approximately 7,000 proteins per sample.
- Roswell Park Comprehensive Cancer CenterkeyClinical trial collaboration to analyze immunotherapy resistance in cancer patients, leveraging Roswell Park's clinical expertise and patient population.
- NHS (UK National Health Service)keyNHS opened eight UK clinical trial sites to assess cancer patient response to immunotherapy in collaboration with OncoHost, enabling international clinical validation.
- RayBiotechsupportingJoint grant partnership awarded $1 million from BIRD Foundation to advance precision oncology for patients receiving immunotherapy, combining proteomic analysis with array technologies.
Scale indicators7 records
Recent moves8 records
Expansion highlights7 records
OncoHost competitors and assessment
Company assessmentDirect peers
- Biodesix: Biodesix develops blood-based diagnostic tests for lung cancer (e.g., Nodify Lung) to guide treatment decisions, directly competing with PROphetNSCLC in the lung cancer diagnostic testing market.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven precision oncology solutions that compete with PROphet for oncologist adoption in therapy selection for advanced cancer patients.
- Personalis: Personalis provides ultra-sensitive liquid biopsy tests for tumor profiling and MRD, overlapping with OncoHost's blood-based approach to inform immunotherapy and oncology treatment decisions.
- Natera: Natera offers Signatera (tumor-informed MRD) and other oncology blood tests, competing in the blood-based oncology diagnostics market and serving oncologists making treatment decisions.
Broad incumbents
- Guardant Health: Guardant Health is an established liquid biopsy company offering comprehensive genomic profiling tests for advanced cancer patients, broadly competing in oncology diagnostics where OncoHost's PROphet also operates.
- Foundation Medicine: Foundation Medicine is a leading molecular diagnostics company providing comprehensive genomic profiling (FoundationOne CDx), serving overlapping oncologist and biopharma customers seeking precision oncology decision support.
- Tempus AI: Tempus AI combines multimodal data (genomics, imaging, clinical) with AI for precision oncology, competing with OncoHost in the AI-driven oncology decision-support space and serving similar oncologist and biopharma customers.
- NeoGenomics: NeoGenomics is an established oncology reference laboratory providing a broad menu of oncology testing services to community hospitals and oncologists, broadly competing with OncoHost's CLIA-certified lab offering.
Emerging players
- Adaptive Biotechnologies: Adaptive Biotechnologies offers immune profiling (clonoSEQ, T-Detect) and is expanding into immune-related oncology applications, with partial overlap to OncoHost's host-response and immunotherapy biomarker focus.
- Olink: Olink provides high-throughput proteomics platforms (Olink Explore) used in biomarker discovery and translational research, serving adjacent proteomics customers and enabling similar cancer biomarker work to OncoHost's SomaScan-based pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OncoHost social profiles
Digital presenceOncoHost compliance and trust
Trust signalCompliance3 records
OncoHost financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoHost leadership team
Management profileNumber of profiles
Profiles10 records
OncoHost subsidiaries and ownership
Company hierarchySubsidiaries1 record
OncoHost funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoHost M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoHost
What does OncoHost do?
OncoHost develops and commercializes the PROphet® platform, an AI-powered plasma proteomics diagnostic that uses the SomaScan assay (measuring ~7,000 circulating proteins per sample) to generate a personalized PROphet® Score predicting clinical benefit from PD-1/PD-L1 inhibitor immunotherapy. The commercially launched PROphetNSCLC® test supports first-line treatment decisions for metastatic non-small cell lung cancer, processed through the company's CLIA-certified laboratory in Cary, North Carolina.
Is OncoHost a public or private company?
OncoHost is a private company. It is classified as venture growth investor backed and is currently operating.
When was OncoHost founded?
OncoHost was founded in 2017. It employs 11 to 50 people.
Where is OncoHost based?
OncoHost is headquartered in Binyamina, Israel, in the Middle East region.
How does OncoHost make money?
One revenue line is on record: laboratory Diagnostic Testing Services.
Who are OncoHost's main competitors?
Direct peers on record are Biodesix, Caris Life Sciences, Personalis and Natera. Broad incumbents are Guardant Health, Foundation Medicine, Tempus AI and NeoGenomics. Emerging players are Adaptive Biotechnologies and Olink.
Does OncoHost have an API?
No public API is recorded for OncoHost.
What industry is OncoHost in?
OncoHost's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 621511 and its SIC code is 2835.